RxDoctor Payments Data

Joseph Lim, MD

Gastroenterology · New Haven, CTNPI 1235112533

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.3%), consulting fees and royalties or licence payments — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Eli Lilly at 50.3% of the total. Reporting peaked in 2021 at $13,520 and has fallen 97.8% since, to $296 in 2024.

$14,316in general payments, 2019–2025

Across 13 payments — averaging $1101.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$7K
  • Gilead$6K
  • Sentynl Therapeutics, Inc.$908
  • Janssen Scientific Affairs, LLC$404
  • Davol Inc.$296
$465,117in research payments, 2019–2025

Across 205 payments — averaging $2268.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$139K
  • AbbVie$103K
  • Pfizer$81K
  • BD$70K
  • Intercept Pharma Europe Ltd.$22K
  • Bristol Myers Squibb$21K
  • plus $29K from 5 others

What the payments were for

  • Royalty or licence$4043%
  • Consulting fees$6,40845%
  • Speaking & faculty fees$7,20850%
  • Food & beverage$2962%

General payments by program year

20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly2$7,208
Gilead2$5,500
Sentynl Therapeutics, Inc.2$908
Janssen Scientific Affairs, LLC1$404
Davol Inc.6$296

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,316 in reported general payments places this provider in the 80th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$16,359
Medicare patients
80
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide60$110,828
Ursodiol22$2,010
Entecavir15$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$5,500$110,82860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →